Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 12, 2025Cancer MedicineOpen Access

Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC‐TFR Study

View Full Paper
Ask AI
Bookmark
Share

Authors

HUHiroshi UreshinoYNYukio NakamuraYBYemima Budirahardja

Discussion

Loading...

Member takes

Overview

Retrospective analysis of TKI discontinuation outcomes in CML patients reveals T-cell immunity may influence treatment-free remission.

Key Points

  • Treatment-free remission (TFR) at one year was observed in 67.9% of CML patients following TKI discontinuation attempts.
  • A second attempt at TKI discontinuation had a much lower TFR rate of 31.2% at one year, indicating challenges in sustained remission.
  • Analysis of T-cell and B-cell receptor repertoires in 14 patients aimed to uncover immune factors related to TFR outcomes.
  • Significant findings include lower relapse risk associated with maintained BCR::ABL1 mRNA levels, suggesting crucial biomarkers for monitoring.

Cite This Study

Ureshino et al. (2025) studied this question.

synapsesocial.com/papers/68c23595b210217d6477124fhttps://doi.org/10.1002/cam4.71142
View Full Paper
Ask AI
Bookmark
Share